Related references
Note: Only part of the references are listed.Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study
Yi-Long Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou et al.
LANCET RESPIRATORY MEDICINE (2021)
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
Qiao Liu et al.
CLINICAL DRUG INVESTIGATION (2020)
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach
Jessica Ochalek et al.
PHARMACOECONOMICS (2020)
Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
Qiao Liu et al.
BMJ OPEN (2020)
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Comparative financing analysis and political economy of noncommunicable diseases
Mihajlo Jakovljevic et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
The impact of health expenditures on public health in BRICS nations
Mihajlo Jakovljevic et al.
JOURNAL OF SPORT AND HEALTH SCIENCE (2019)
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
Xiaohua Gu et al.
LUNG CANCER (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Health state utilities in patients with advanced non-small-cell lung cancer in China
Yunjie Shen et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2018)
Health state utilities in non-small cell lung cancer: An international study
Beenish Nafees et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of historical medical spending patterns among the BRICS and G7
Mihajlo Michael Jakovljevic
JOURNAL OF MEDICAL ECONOMICS (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Quality-of-life and health utility scores for common cancers in China: a multicentre cross-sectional survey
Ju-Fang Shi et al.
LANCET (2016)
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
Caicun Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
BRIC's growing share of global health spending and their diverging pathways
Mihajlo B. Jakovljevic
FRONTIERS IN PUBLIC HEALTH (2015)
Improved curve fits to summary survival data: application to economic evaluation of health technologies
Martin W. Hoyle et al.
BMC MEDICAL RESEARCH METHODOLOGY (2011)
Share Paper
